DIEBOLD NIXDORF INC (DBD) Fundamental Analysis & Valuation

NYSE:DBD • US2536512021

77.58 USD
-0.95 (-1.21%)
At close: Mar 6, 2026
77.58 USD
0 (0%)
After Hours: 3/6/2026, 8:10:43 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This DBD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Taking everything into account, DBD scores 4 out of 10 in our fundamental rating. DBD was compared to 36 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has only an average score on both its financial health and profitability. DBD has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

5

1. DBD Profitability Analysis

1.1 Basic Checks

  • DBD had positive earnings in the past year.
  • In the past year DBD had a positive cash flow from operations.
  • In the past 5 years DBD reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
DBD Yearly Net Income VS EBIT VS OCF VS FCFDBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • DBD has a better Return On Assets (1.36%) than 66.67% of its industry peers.
  • DBD has a better Return On Equity (4.57%) than 77.78% of its industry peers.
  • DBD's Return On Invested Capital of 8.85% is fine compared to the rest of the industry. DBD outperforms 69.44% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for DBD is significantly below the industry average of 16.73%.
  • The last Return On Invested Capital (8.85%) for DBD is above the 3 year average (5.12%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.36%
ROE 4.57%
ROIC 8.85%
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
DBD Yearly ROA, ROE, ROICDBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

  • Looking at the Profit Margin, with a value of 1.37%, DBD is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 7.47%, DBD is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • DBD's Operating Margin has improved in the last couple of years.
  • DBD has a Gross Margin (25.48%) which is in line with its industry peers.
  • DBD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 7.47%
PM (TTM) 1.37%
GM 25.48%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
DBD Yearly Profit, Operating, Gross MarginsDBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. DBD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DBD is destroying value.
  • DBD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DBD Yearly Shares OutstandingDBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
DBD Yearly Total Debt VS Total AssetsDBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

  • DBD has an Altman-Z score of 2.05. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • DBD has a Altman-Z score (2.05) which is comparable to the rest of the industry.
  • The Debt to FCF ratio of DBD is 3.71, which is a good value as it means it would take DBD, 3.71 years of fcf income to pay off all of its debts.
  • DBD has a better Debt to FCF ratio (3.71) than 66.67% of its industry peers.
  • DBD has a Debt/Equity ratio of 0.84. This is a neutral value indicating DBD is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.84, DBD perfoms like the industry average, outperforming 41.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 3.71
Altman-Z 2.05
ROIC/WACC0.95
WACC9.31%
DBD Yearly LT Debt VS Equity VS FCFDBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

  • DBD has a Current Ratio of 1.36. This is a normal value and indicates that DBD is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of DBD (1.36) is comparable to the rest of the industry.
  • A Quick Ratio of 0.89 indicates that DBD may have some problems paying its short term obligations.
  • DBD has a Quick ratio of 0.89. This is comparable to the rest of the industry: DBD outperforms 50.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.36
Quick Ratio 0.89
DBD Yearly Current Assets VS Current LiabilitesDBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. DBD Growth Analysis

3.1 Past

  • DBD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.93%, which is quite impressive.
  • DBD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 48.24% yearly.
EPS 1Y (TTM)40.93%
EPS 3YN/A
EPS 5Y48.24%
EPS Q2Q%183.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.66%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.64% on average over the next years. This is quite good.
  • Based on estimates for the next years, DBD will show a small growth in Revenue. The Revenue will grow by 2.76% on average per year.
EPS Next Y-9.64%
EPS Next 2Y9.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.28%
Revenue Next 2Y2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
DBD Yearly Revenue VS EstimatesDBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B
DBD Yearly EPS VS EstimatesDBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. DBD Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 14.26, the valuation of DBD can be described as correct.
  • Based on the Price/Earnings ratio, DBD is valued cheaply inside the industry as 86.11% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.29. DBD is valued slightly cheaper when compared to this.
  • Based on the Price/Forward Earnings ratio of 15.78, the valuation of DBD can be described as correct.
  • DBD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DBD is cheaper than 66.67% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.57, DBD is valued a bit cheaper.
Industry RankSector Rank
PE 14.26
Fwd PE 15.78
DBD Price Earnings VS Forward Price EarningsDBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • DBD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DBD is cheaper than 91.67% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, DBD is valued cheaper than 83.33% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.06
EV/EBITDA 8.45
DBD Per share dataDBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.3
EPS Next 2Y9.64%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DBD Dividend Analysis

5.1 Amount

  • No dividends for DBD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DBD Fundamentals: All Metrics, Ratios and Statistics

DIEBOLD NIXDORF INC

NYSE:DBD (3/6/2026, 8:10:43 PM)

After market: 77.58 0 (0%)

77.58

-0.95 (-1.21%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)02-12
Earnings (Next)05-05
Inst Owners105.4%
Inst Owner Change-2.29%
Ins Owners1.81%
Ins Owner Change-0.17%
Market Cap2.78B
Revenue(TTM)N/A
Net Income(TTM)50.60M
Analysts82.86
Price Target98.6 (27.09%)
Short Float %2.37%
Short Ratio3.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)22.36%
PT rev (3m)22.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)13.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.36%
Valuation
Industry RankSector Rank
PE 14.26
Fwd PE 15.78
P/S 0.75
P/FCF 11.06
P/OCF 9.96
P/B 2.51
P/tB N/A
EV/EBITDA 8.45
EPS(TTM)5.44
EY7.01%
EPS(NY)4.92
Fwd EY6.34%
FCF(TTM)7.01
FCFY9.04%
OCF(TTM)7.79
OCFY10.04%
SpS102.88
BVpS30.87
TBVpS-9.56
PEG (NY)N/A
PEG (5Y)0.3
Graham Number61.47
Profitability
Industry RankSector Rank
ROA 1.36%
ROE 4.57%
ROCE 11.2%
ROIC 8.85%
ROICexc 9.91%
ROICexgc 29.15%
OM 7.47%
PM (TTM) 1.37%
GM 25.48%
FCFM 6.82%
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF 3.71
Debt/EBITDA 2.28
Cap/Depr 20.59%
Cap/Sales 0.75%
Interest Coverage 2.89
Cash Conversion 68.06%
Profit Quality 497.23%
Current Ratio 1.36
Quick Ratio 0.89
Altman-Z 2.05
F-Score7
WACC9.31%
ROIC/WACC0.95
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.93%
EPS 3YN/A
EPS 5Y48.24%
EPS Q2Q%183.51%
EPS Next Y-9.64%
EPS Next 2Y9.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.66%
Revenue Next Year2.28%
Revenue Next 2Y2.76%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.55%
EBIT Next 3Y13.91%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%

DIEBOLD NIXDORF INC / DBD FAQ

What is the fundamental rating for DBD stock?

ChartMill assigns a fundamental rating of 4 / 10 to DBD.


Can you provide the valuation status for DIEBOLD NIXDORF INC?

ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.


What is the profitability of DBD stock?

DIEBOLD NIXDORF INC (DBD) has a profitability rating of 5 / 10.


What is the financial health of DIEBOLD NIXDORF INC (DBD) stock?

The financial health rating of DIEBOLD NIXDORF INC (DBD) is 4 / 10.


How sustainable is the dividend of DIEBOLD NIXDORF INC (DBD) stock?

The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.